Cancer is a complex disease of more than 100 types that affect 1.7 million people and families every year. Molecular profiling of circulating biomarkers holds great promise for early cancer detection due to its ability to provide non-invasive snapshots of the tumors before they can be detected by conventional techniques such as imaging or biopsy. But, despite billions of R&D investments in the past decades, current molecular diagnostic technologies have not yet delivered on this promise.
Traditional molecular profiling is:
Rely too heavily on qPCR and/or next-gen sequencing technologies, which are highly complex, expensive, and time-consuming;
Traditional molecular profiling is: And each technology rely on a single type of biomarker (either DNA, microRNA or protein) to identify specific types of cancer, whereas cancer is a complex group of more than 100 diseases with multiple mutations whose pathways are not yet well-understood.
At ConquerX, we believe that we should look to the cancer diagnostic with a new perspective. Instead of specific tests for more than 100 types of cancer, we believe on the pan-cancer test, where it is possible to screen for biomarkers related to cancer cells versus healthy cells. And with this approach, save millions of people that are now being diagnosed by chance.
Expertise in biosensors
Expertise in software engineering MIT
Expertise in cancer research
MD Anderson Cancer Center
25+ yrs exp working in startups
Undergone IPO/acquisition process
MIT Professor of Materials Science & Engineering
Published 80+ scientific papers
Chief of Marketing Officer @ Fonetic
B2B & Sales Expertise
Previous Chief of Surgery @ Maxima Medical Center
Founded Specialty Physian Group
Harvard Business School